- Home
- EMO vs TRVI Comparison
EMO vs TRVI Comparison
Compare EMO & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMO
- TRVI
- Stock Information
- Founded
- EMO 2011
- TRVI 2011
- Country
- EMO United States
- TRVI United States
- Employees
- EMO N/A
- TRVI N/A
- Industry
- EMO Investment Managers
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- EMO Finance
- TRVI Health Care
- Exchange
- EMO Nasdaq
- TRVI Nasdaq
- Market Cap
- EMO 863.9M
- TRVI 725.7M
- IPO Year
- EMO N/A
- TRVI 2019
- Fundamental
- Price
- EMO $46.08
- TRVI $8.54
- Analyst Decision
- EMO
- TRVI Strong Buy
- Analyst Count
- EMO 0
- TRVI 9
- Target Price
- EMO N/A
- TRVI $20.72
- AVG Volume (30 Days)
- EMO 27.1K
- TRVI 3.2M
- Earning Date
- EMO 01-01-0001
- TRVI 11-05-2025
- Dividend Yield
- EMO 6.70%
- TRVI N/A
- EPS Growth
- EMO N/A
- TRVI N/A
- EPS
- EMO N/A
- TRVI N/A
- Revenue
- EMO N/A
- TRVI N/A
- Revenue This Year
- EMO N/A
- TRVI N/A
- Revenue Next Year
- EMO N/A
- TRVI N/A
- P/E Ratio
- EMO N/A
- TRVI N/A
- Revenue Growth
- EMO N/A
- TRVI N/A
- 52 Week Low
- EMO $26.42
- TRVI $2.36
- 52 Week High
- EMO $40.17
- TRVI $9.92
- Technical
- Relative Strength Index (RSI)
- EMO 37.06
- TRVI 57.72
- Support Level
- EMO $45.82
- TRVI $7.65
- Resistance Level
- EMO $47.20
- TRVI $8.28
- Average True Range (ATR)
- EMO 0.82
- TRVI 0.66
- MACD
- EMO -0.21
- TRVI 0.03
- Stochastic Oscillator
- EMO 9.33
- TRVI 53.85
About EMO ClearBridge Energy Midstream Opportunity Fund Inc.
ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions. The Fund considers investments in midstream entities as those entities that provide midstream services including the gathering, transporting, processing, fractionation, storing, refining, and distribution of oil, natural gas liquids and natural gas.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.